Answers are grounded in this paper and cite their sources.
Various points were discussed by the 22 participants in the Symposium (doctors, statisticians and pharmacologists) under the following main headings: choice of subjects for a clinical trial, choice of treatments, criteria of assessment, trial design and “optimum” number of subjects. Difficulties most frequently met in each of these areas, open problems and hints at solutions are briefly reviewed in the report, special attention being paid to the alternative (especially relevant and critical in such fields as cancer clinical experimentation) between the two attitudes which are possible in a clinical trial context: the “explanatory” attitude (aimed at gaining basic knowledge about treatments) and the “pragmatic” attitude (aimed at guiding the decision on how to treat particular patients).
No takes yet. Share an insight, caveat, or question.
Healy et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: